Centessa Pharmaceuticals (STU:260) Debt-to-Equity : 0.40 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals Debt-to-Equity?

Centessa Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.49 Mil. Centessa Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €78.70 Mil. Centessa Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €197.95 Mil. Centessa Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2024 was 0.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Centessa Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

STU:260' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.25 Med: 0.2 Max: 0.4
Current: 0.4

During the past 5 years, the highest Debt-to-Equity Ratio of Centessa Pharmaceuticals was 0.40. The lowest was -0.25. And the median was 0.20.

STU:260's Debt-to-Equity is ranked worse than
71.16% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs STU:260: 0.40

Centessa Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Centessa Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centessa Pharmaceuticals Debt-to-Equity Chart

Centessa Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

N/A

-0.25

0.15

0.21

0.36

Centessa Pharmaceuticals Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial										0.28	0.30	0.32	0.36	0.40

Competitive Comparison of Centessa Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Centessa Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Centessa Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Centessa Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Centessa Pharmaceuticals's Debt-to-Equity falls into.

Centessa Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Centessa Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	77.567)	/	216.636
	=	0.36

Centessa Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.486	+	78.7)	/	197.95
	=	0.40

Centessa Pharmaceuticals (STU:260) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Centessa Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Centessa Pharmaceuticals (STU:260) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (STU:260) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

CNTA:USA

Address

1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT

Website

https://www.centessa.com

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Centessa Pharmaceuticals (STU:260) Headlines

No Headlines